📢 Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round. The funding will be used to support the clinical development of MEM-ANT3310, a next generation antibacterial combination. It is designed to provide unique coverage of priority Gram-negative pathogens. Antabio’s portfolio also includes two other programs for the treatment of various infections.
📢 Antabio SAS raises €25m for groundbreaking antibacterial treatment
Antabio SAS, an antibiotics specialist, has raised €25 million in a Series B financing round. The funding will be used to support the clinical development of MEM-ANT3310, a next-generation antibacterial combination designed to provide unique coverage of priority Gram-negative pathogens. MEM-ANT3310 combines the carbapenem meropenem with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor. Antabio’s portfolio also includes two other programs: ANT3273, a novel inhalation treatment for Pseudomonas aeruginosa infections, and ANT2681, a metallo beta-lactamase (MBL) inhibitor. The financing will help advance the fight against antimicrobial resistance (AMR), which is recognized as a top priority by the World Health Organization.
